Relmada Therapeutics, Inc. RLMD
Institutional shares held
6.3 Million
0
calls
0
puts
Total value of holdings
$3.78M
$0
calls
$0
puts
Market Cap
$17.2M
28,608,500
Shares Out.
Institutional ownership
22.01%
# of Institutions
49
We take great care to ensure that the data presented and summarized in this overview for RELMADA THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RLMD
View all-
Acadian Asset Management LLC Boston, MA1.23MShares$736,7560.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$724,8450.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$343,9880.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$297,0870.03% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$181,1290.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny288KShares$172,8000.0% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD277KShares$165,9080.02% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M225KShares$134,9070.0% of portfolio
-
Two Sigma Investments, LP New York, NY171KShares$102,3260.0% of portfolio
-
Parsons Capital Management Inc163KShares$98,0010.01% of portfolio
Latest Institutional Activity in RLMD
Top Purchases
Top Sells
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Insider Transactions at RLMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
147,686
+16.75%
|
$0
$0.56 P/Share
|
|
May 20
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+17.22%
|
$0
$0.52 P/Share
|
|
May 19
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+4.87%
|
$0
$0.5 P/Share
|
|
May 19
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
90,000
+28.27%
|
$0
$0.49 P/Share
|
|
May 16
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
172,314
+23.65%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
228,961
+46.08%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+26.55%
|
$0
$0.44 P/Share
|
|
May 16
2025
|
Paul Edward Kelly Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
200,000
+32.66%
|
$0
$0.43 P/Share
|
|
Oct 22
2024
|
Charles J Casamento Director |
SELL
Bona fide gift
|
Direct |
13,000
-100.0%
|
-
|
|
Sep 11
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,120
+21.45%
|
$48,240
$2.95 P/Share
|
|
Sep 11
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
51,407
+11.81%
|
$102,814
$2.99 P/Share
|
|
Sep 10
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
21,118
+24.75%
|
$42,236
$2.73 P/Share
|
|
Sep 10
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
33,014
+9.03%
|
$66,028
$2.75 P/Share
|
|
Sep 09
2024
|
Paul Edward Kelly Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+10.54%
|
$50,000
$2.59 P/Share
|
|
Sep 09
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,194
+15.98%
|
$16,388
$2.55 P/Share
|
|
Sep 09
2024
|
Charles J Casamento Director |
BUY
Open market or private purchase
|
Direct |
13,000
+50.0%
|
$26,000
$2.56 P/Share
|
|
Sep 09
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
55,579
+15.65%
|
$111,158
$2.71 P/Share
|
|
Jan 31
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
13,670
+25.97%
|
$54,680
$4.05 P/Share
|
|
Jan 31
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
6,875
+16.46%
|
$27,500
$4.06 P/Share
|
|
Jan 31
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,460
+10.11%
|
$109,840
$4.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.21M
Shares
From
5
Insiders
| Open market or private purchase | 1.21M shares |
|---|
Sell / Disposition
13K
Shares
From
1
Insiders
| Bona fide gift | 13K shares |
|---|